Dates: 18 September 2023
The Scientific Colloquium brings together a panel of scientific experts from Afrigen and the University of Marseille who will present on key scientific findings from mRNA technology transfer programme. This includes work on plasmids, drug substance and drug product, analytics and the hamster study findings. The session will also look forward at sustainability and the pipeline of potential vaccines and next generation technologies. A discussion will follow, that includes panelists from VCR/NIH, programme partners, CEPI, DCVMN, MPP and WHO. The in-person event will be followed by a networking reception. The Afrigen facilities can be explored through a photographic exhibit, 3D video presentations with access to some of the open areas of equipment.
Click Here to Register to join In-person: bit.ly/3rmZOBj
Click Here to Register to join online via Zoom: bit.ly/3PVa265
Includes networking sessions with canape dinner, 3D virtual tour headset viewing – new PVA film on the mRNA technology, photo exhibition of the inside of the labs at Afrigen and visit to external equipment available to see (Posters of lab layout, Ntensify™ Midi System machine, cryogenic cell banks).
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.